NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...

NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the ...

Stealth BioTherapeutics Provides Commercial and R&D Pipeline Update and Outlines 2026 Strategic Priorities

Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, ...
TipRanks on MSN

Thiogenesis to showcase mitochondrial disease clinical progress at UMDF webinar

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...
New Atlas

First proof brain’s powerhouses drive – and can reverse – dementia symptoms

Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made a huge breakthrough, proving for the first time how mitochondrial ...
technologynetworks

Seahorse XF Mito Tox Assay: Assess Drug-Induced Mitochondrial Dysfunction Using Primary Hepatocytes

The Agilent Seahorse XF Mito Tox Assay kit is a powerful tool for identifying drug-induced mitochondrial toxicity by directly measuring mitochondrial oxygen consumption rates (OCR). Mitochondrial ...
Endocrinology Advisor

AHA Scientific Statement Links Mitochondrial Genetic Variants to CVD

The AHA recommended whole exome or whole genome sequencing as first-line diagnostic tools for mitochondrial diseases.